Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the Biomarkers Series UK 2020 conference in Manchester, UK, February 19-20.
The presentation , titled “Maximizing Immunotherapy Biomarker Discovery with an Advanced Tumor Immunogenomics Platform,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT ™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.
ImmunoID NeXT ™ is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a single tumor specimen.
Personalis will also be exhibiting during the conference (Exhibit #38). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
P&G27.3.2020 15:16:05 CET | Press release
P&G Joins Forces with the Red Cross and Red Crescent Network to Provide Emergency Relief and Serve European Communities During COVID-19 Pandemic
NY-DILIGENT27.3.2020 15:02:05 CET | Press release
Diligent Offers Seamless Video Conferencing Access Across All Board Management Platforms to Ensure Secure, Virtual Board Meetings as the Workforce Shifts Remote
ALPEGA-GROUP27.3.2020 13:07:08 CET | Press release
Teleroute Opens Its Freight Exchange Platform to Help Transport Companies During Current Crisis
CA-DELTATRAK27.3.2020 13:02:08 CET | Press release
DeltaTrak Announces New Non-Contact Forehead Infrared Thermometer to Aid in Coronavirus Prevention
TX-MARY-KAY26.3.2020 23:03:08 CET | Press release
Mary Kay Manufactures, Donates Hand Sanitizer to Combat COVID-19 Pandemic
DAWEX26.3.2020 22:54:08 CET | Press release
COVID-19 Data Exchange to Curb the Virus’ Propagation and Limit Its Economic Impact
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom